Neurodegenerative diseases are our first priority, with a special emphasis on Alzheimer’s Dementia (AD) associated with beta-amyloid and tau oligomers and fibrils, Parkinson’s Disease (PD) with α-synuclein oligomers and fibrils, Creutzfeldt–Jakob Disease (CJD) with abnormal prion proteins, and Huntington’s Disease (HD) with misfolding and aggregation of “huntingtin” proteins. SynAging’s scientists have contributed towards the understanding of which aggregates are toxic and what could be the mechanism of neurodegeneration.
Successful drug development requires the use of relevant disease models. SynAging endeavors to offer in vitro and in vivo models for all these diseases, which most accurately represent the biochemical cause of the disease under investigation. In this context, SynAging scientists are constantly monitoring the scientific literature adapting new scientific insights into disease mechanisms.
SynAging’s in vitro models are often used for hit validation following biochemical screens, investigating tens to hundreds of potential lead candidates for activity in relevant phenotypic disease models and giving a first indication towards their potency.
SynAging’s in vivo models are further used for lead selection and optimization, taking more advanced drug candidates into animal models that investigate multiple disease relevant behaviors and read-outs.
SynAging is specialized on protein aggregate caused human disease. Such diseases are often called 'amyloidosis' and recently also proteopathic or proteinopathic diseases, and comprise a number of incurable degenerative diseases. The protein aggregates are not degradable in the human body and accumulate often causing cell malfunctioning or death.
Neurodegenerative diseases are SynAging’s main focus, with unique capabilities in Alzheimer’s Dementia (AD) and Parkinson's disease (PD). SynAging’s scientists are constantly expaning our service portfolio and contributing towards the understanding of these diseases.
For further information please choose the disease of interest from the menu on the left.